Salute e Benessere
Glucagon-Like Peptide-1 Analogues Market to Surpass USD 299.08 Billion by 2033, Fueled by the Weight Management and Diabetes Revolution | DataM Intelligence
The GLP-1 analogues market is being reshaped by intersecting public health trends- and the . According to DataM Intelligence, over are now classified as obese, while diabetes affects , intensifying the need for multi-target therapeutic options.
The global GLP-1 analogues market is segmented
The (marketed under Ozempic, Wegovy, and Rybelsus) dominated the product landscape in 2024, accounting for over , equivalent to approximately . These drugs have set new standards for efficacy, with average weight loss of 15–20% observed in clinical trials.
(Saxenda, Victoza) represented the second-largest share, though their growth has plateaued due to next-generation replacements. Emerging competitors like -a dual GLP-1/GIP receptor agonist-are projected to capture nearly by 2027, driven by superior weight loss efficacy and growing regulatory approvals.
Based on molecular structure and modification, the market is classified into and . Long-acting analogues, such as semaglutide and dulaglutide, dominate with approximately in 2024 due to lower injection frequency and sustained glycemic control. Short-acting analogues like exenatide retain niche use for postprandial glucose regulation.
Injectable formulations continue to account for nearly ( USD 53 billion in 2024). However, -led by Rybelsus (oral semaglutide)-are expected to expand rapidly, growing at over through 2033. The convenience of daily oral dosing is anticipated to attract a new segment of non-insulin-dependent diabetic patients and weight management consumers.
While remains the dominant indication, representing , the is witnessing exponential growth, projected to rise from . This transition reflects the shifting therapeutic focus of GLP-1 analogues from glucose regulation to holistic metabolic management.
Emerging applications include and , both under active clinical evaluation by key industry leaders.
In 2024, represented nearly , while accounted for the remaining share. The online channel is expanding rapidly due to growing direct-to-consumer telemedicine platforms offering prescription weight-loss programs.
The United States dominates the global GLP-1 analogues market, accounting for nearly , equivalent to . The U.S. has witnessed explosive adoption due to the unprecedented popularity of weight-loss drugs such as Wegovy and Mounjaro, coupled with favorable reimbursement policies and expanded production capacity by leading pharmaceutical firms.
As a result, U.S. prescriptions for GLP-1 analogues surged between 2023 and 2024, marking one of the fastest adoption cycles in pharmaceutical history.
Japan is emerging as a major growth frontier for GLP-1 therapies, particularly driven by a rise in obesity rates among adults aged 35–60. The Japanese GLP-1 market reached , representing approximately , and is projected to exceed .
The GLP-1 analogues market is dominated by a few key players, with and together holding over as of 2024. However, new entrants and regional biopharma companies are actively developing differentiated delivery systems and combination therapies to capture emerging niches.
Eli Lilly and Company, Novo Nordisk A/S, Sanofi, AstraZeneca, Boehringer Ingelheim, Glenmark Pharmaceuticals Ltd., Hanmi Pharm Co., Ltd., Amgen Inc., Gmax Biopharm, and Sciwind Biosciences Co., Ltd.
Together, these companies represent the backbone of the rapidly expanding GLP-1 ecosystem, supported by over targeting diabetes, obesity, and metabolic syndrome.
DataM Intelligence projects that the GLP-1 analogues market will continue its meteoric rise as beyond diabetes into . The industry's next phase will be defined by innovations in , , and .
The stands at the epicenter of the global pharmaceutical revolution, redefining chronic disease management and reshaping the future of metabolic care.
According to , with a market poised to surge from to , the next decade will witness continued innovation, patient access expansion, and strategic collaborations among industry leaders. As GLP-1 therapies evolve from injectable to oral and combination formats, they are set to transform healthcare outcomes for millions battling diabetes, obesity, and associated metabolic disorders worldwide.
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com or follow us on Twitter, LinkedIn and Facebook.
Sai Kiran
DataM Intelligence 4 Market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/glucagon-like-peptide-1-analogues-market-to-surpass-usd-299-08-billion-by-2033--fueled-by-the-weight-management-and-diabetes-revolution--datam-intelligence-302596816.html